Can T-Cell Science Fix What Biologics Cannot?

UCB acquires Candid Therapeutics for up to $2.2B, betting T-cell engager science can reset autoimmune disease, not just manage it

2 Jun 2026

Belgium's UCB has placed a $2.2 billion wager on a different theory of autoimmune disease. The May deal to acquire Candid Therapeutics brings in a clinical-stage biotech building antibodies designed to reset the immune system, not simply quiet it. Where existing biologics suppress inflammation, Candid's platform aims at the source: the plasma cells responsible for the immune system attacking itself.

Central to the acquisition is cizutamig, a bispecific antibody that redirects a patient's own T-cells toward those rogue plasma cells. Phase 1 trials are underway across multiple indications. Before any single condition was prioritized, the pipeline of bispecific and trispecific candidates was tested deliberately across diverse immune-mediated settings, a methodical approach that reflects the complexity of what Candid is attempting.

UCB pays $2 billion upfront. By year's end, the deal will be its third major external move of 2026, following a $1.15 billion acquisition of Neurona Therapeutics and a licensing agreement with Antengene. The pace signals conviction. Critics, however, are right to flag the risk: phase 1 data, however mechanistically promising, rarely predicts commercial success against entrenched biologics with years of physician trust behind them.

The technical demands outside oncology add another layer. Molecular stability, immune overreaction management, and patient-friendly formulations must be engineered into the platform long before late-stage trials arrive. Drug delivery decisions, often underestimated, will shape outcomes as much as the underlying biology does.

Hundreds of millions of people live with autoimmune conditions that current medicine manages without resolving. UCB is betting that immune-reset therapy has moved far enough from theory to justify that price.